Applying SiSu® to Our Pipeline

RBLP is a twice-yearly intravitreally administered formulation of latanoprost for the treatment of mild-to-moderate primary open-angle glaucoma. Topical (eye drops) latanoprost is the most common first-line treatment for newly diagnosed patients. If approved, RBLP could transform the way POAG is treated by providing sustained treatment without the risk of non-adherence and potential local (surface) side effects.

RBDX is a subconjunctivally administered formulation of dexamethasone for the prophylaxis of postoperative inflammation following glaucoma and corneal transplantation surgery, providing a targeted tapering release over 3 months. If approved, RBDX could replace the current paradigm of a surgical injection of dexamethasone followed by a 3-6 month course of topical steroids, administered several times per day, which is necessary to attenuate the natural healing response which may lead to fibrosis and surgical failure.

RBTKi is an intravitreally administered tyrosine kinase inhibitor, designed to be administered twice-yearly for the treatment of diabetic macular edema. While the value of treatment of DME and other retinal diseases with this potent class of anti-VEGF inhibitors has been extensively studied, there has been little success in delivering it as an effective treatment. ReBio believes that the SiSu® platform is ideally suited to the sustained delivery of therapeutic levels of these potent therapeutics, and is evaluating selected compounds to bring forward into pre-clinical studies.

ReBio’s Pipeline Follows an Accelerated, FDA-Vetted, Progressively De-Risked, High-Value Development Strategy to Address Unmet and Undermet Clinical Needs

ReBio continues to evaluate opportunities to leverage the SiSu® platform for the treatment of chronic eye diseases through collaboration with private and academic researchers. Targets currently under evaluation include approved systemic therapies repurposed as targeted treatments for ocular diseases, as well as novel moieties for the treatment of rare diseases. For more information, or to explore collaboration with ReBio, please contact us at info@rebiopharma.com